<DOC>
	<DOCNO>NCT01275599</DOCNO>
	<brief_summary>The purpose study investigate drug-drug interaction potential telaprevir buprenorphine/naloxone . An understanding interaction potential help determine whether buprenorphine dose adjustment necessary patient concomitantly treat telaprevir . Telaprevir , combination antiviral agent , investigate treatment chronic hepatitis C virus infection . Buprenorphine/naloxone use maintainance therapy patient opioid dependence .</brief_summary>
	<brief_title>Drug-Drug Interaction Study Between Telaprevir Buprenorphine</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Buprenorphine , Naloxone Drug Combination</mesh_term>
	<criteria>Males female age 18 64 year , inclusive . Females must nonchildbearing potential . Receiving daily buprenorphine/naloxone maintenance therapy stable dose exceed 24 mg/6 mg , respectively , least 2 week prior screen . Illicit use drug cocaine , amphetamine methylenedioxymethamphetamine ( MDMA ) , barbiturates , benzodiazepine , tricyclic antidepressant , methadone opiates/opioids ( apart buprenorphine ) . Treatment investigational drug within last 30 day , 5 halflives , whichever longer . Blood donation 500 mL within last 56 day . Infected hepatitis B virus , hepatitis C virus , human immunodeficiency virus ( HIV ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>